Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913 and ONO-4538 plus modified FOLFIRINOX in first-line metastatic pancreatic cancer
jRCT2031210172Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of magrolimab, nivolumab and FOLFIRINOX in pancreatic cancer (PC), sponsored by Ono Pharmaceutical. Primary endpoints: Tolerability and Safety. Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031210172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210172.